Speaker Profile
M.D., Ph.D., Co-Founder and CEO, Noetik
Biography
Ron Alfa is a physician scientist at the forefront of leveraging technology to tackle unmet therapeutic needs in medicine. He is Co-Founder and CEO of NOETIK, a next generation precision oncology company using multimodal foundation models pre-trained on large-scale human tumor data to discover cancer therapeutics. Prior to founding Noetik, Ron was Senior Vice President, Head of Research and acting-CSO at Recursion, where he led the company’s scientific organizations and portfolio strategy. At Recursion, he led portfolio and platform builds across rare disease, neuroscience, oncology, and immunology, and was responsible for advancing multiple therapeutic programs from discovery to clinical development. Ron holds an MD and PhD from Stanford University School of Medicine, where he completed his doctoral work in Neuroscience, and has a MA in History of Medicine from UCL.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures & Gad Getz, Broad Institute
PMWC Award Ceremony
• David Baker, University of Washington (Nobel Laureate, Luminary)
Featured Speakers
• David Baker, University of Washington
• Jack Dent, Chai Discovery
• Dimitri Yatsenko, DataJoint
• Evgeny Kiner, Neosplice Therapeutics
• Alex Morgan, Khosla Ventures
• Gad Getz, Broad Institute
Causal Targets, Not Just Better Molecules
Using AI and human biology to improve target selection before chemistry begins.
Data Is the Moat
What proprietary, longitudinal, and perturbational data really confer advantage.
From Prediction to Patient
Patient stratification, smarter trials, and the handoff from model to clinic.
Designed Biology Meets Drug Development
AI-designed proteins, developability, and what survives contact with reality.
The Target Discovery Bottleneck
Why splicing and other underused biology may expand what is druggable.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
